Ranked by reported Q1 2024 13F market value
Share of total reported institutional value in SLRX held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 84K | $44K | — | 130.297% | 0.00% |
| 2 | HORIZON KINETICS ASSET MANAGEMENT LLC | 31K | $16K | — | 48.232% | 0.00% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 25K | $13K | -91.1% | 38.424% | 0.00% |
| 4 | VANGUARD GROUP INC | 15K | $8K | -99.1% | 22.590% | 0.00% |
| 5 | Tower Research Capital LLC (TRC) | 8K | $4K | +6138.5% | 13.064% | 0.00% |
| 6 | ADVISOR GROUP HOLDINGS, INC. | 1K | $733 | -93.9% | 2.151% | 0.00% |
| 7 | MORGAN STANLEY | 60 | $32 | -100.0% | 0.093% | 0.00% |
| 8 | WELLS FARGO & COMPANY/MN | 31 | $16 | -88.2% | 0.048% | 0.00% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 28K | $15 | — | 43.808% | 0.00% |
| 10 | UBS Group AG | 18 | $10 | -99.7% | 0.028% | 0.00% |
| 11 | BANK OF AMERICA CORP /DE/ | 16 | $8 | -11.1% | 0.025% | 0.00% |
| 12 | BlackRock Inc. | 15 | $8 | -100.0% | 0.023% | 0.00% |
| 13 | FMR LLC | 7 | $4 | +600.0% | 0.011% | 0.00% |
| 14 | CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | — | 0.000% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in SLRX — a direct measure of their conviction.
Filings activity in SLRX during Q1 2024, grouped by how each filer changed its position.
Institutions that opened a new SLRX position in Q1 2024
Institutions that fully closed their SLRX position in Q1 2024
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2024 | 14 | 60% | 182.47% | 17.52 pp | $0M | 99% |
| Q2 2021 | 35 | +2.9% | 199.99% | +0.00 pp | $11M | 53% |
| Q1 2021 | 34 | +31% | 199.99% | +0.00 pp | $23M | +488% |
| Q4 2020 | 26 | +37% | 199.99% | +0.00 pp | $4M | +516% |
| Q3 2020 | 19 | +19% | 199.99% | +0.00 pp | $1M | 1.1% |
| Q2 2020 | 16 | 11% | 199.99% | +0.00 pp | $1M | +20% |
| Q1 2020 | 18 | +13% | 199.99% | +0.00 pp | $1M | 37% |
| Q4 2019 | 16 | — | 199.99% | — | $1M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying SLRX stock.
Based on Q1 2024 13F filings, institutional ownership of Salarius Pharmaceuticals, Inc. stands at 182.5%, held across 14 reporting institutions.
ARMISTICE CAPITAL, LLC is the largest reported institutional holder of SLRX, with approximately 84,000 shares worth $0.00B as of Q1 2024.
Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of SLRX, including RENAISSANCE TECHNOLOGIES LLC.
Our composite Smart Money Score for SLRX is 23 out of 100 (Bearish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in SLRX during Q1 2024, while 24 fully exited. 0 added to existing positions and 6 trimmed.
SLRX institutional ownership fell by 17.52 percentage points quarter-over-quarter, with a net change of -21 holders.
The top 10 institutions account for 100.0% of all reported 13F value in SLRX, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Salarius Pharmaceuticals, Inc. (SLRX) Institutional Ownership